â– LECTURE OVERVIEW: Schizophrenia is a chronic, heterogeneous psychiatric disorder characterized by a disintegration of thought processes and emotional responsiveness.
â– DOPAMINERGIC PATHWAYS & RECEPTORS:
1. Positive Symptoms (Excess/distortion of normal function):
- Manifestations: Hallucinations, delusions, disorganized speech, and grossly disorganized behavior.
- Pathway: Driven by dopamine hyperactivity at D2 receptors selectively in the Mesolimbic pathway of the brain.
2. Negative Symptoms (Loss of normal function):
- Manifestations: Apathy, flat affect, alogia (poverty of speech), anhedonia, and social withdrawal.
- Pathway: Driven by relative dopamine hypoactivity at D1 receptors in the Mesocortical pathways.
â– EPIDEMIOLOGICAL PROFILE & PREVALENCE METRICS:
Global burden mapping indicates significant geographic, ethnic, and temporal patterns. Incidence statistics reveal correlation with environmental lifestyle stressors, socio-economic vectors, and genetic founder effects.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1015]
🌟 Dynamic Clinical Key:
First-generation antipsychotics (e.g., Haloperidol, Chlorpromazine) are potent D2 blockers that treat positive symptoms but can worsen negative symptoms and cause extrapyramidal side effects. Second-generation atypical antipsychotics (e.g., Aripiprazole, Clozapine, Olanzapine) block 5-HT2A receptors alongside D2, offering better management of negative symptoms. Utilize standardized screening questionnaires across highly endemic populations to detect early subclinical cases. Assess demographic representation when applying trial results to real-world patients.